Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy

David Pace*, Ameneh Khatami, Simon Attard-Montalto, Merryn Voysey, Adam Finn, Saul N. Faust, Paul T. Heath, Ray Borrow, Matthew D. Snape, Andrew J. Pollard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background Use of a polysaccharide vaccine challenge to demonstrate immunologic memory after priming with capsular group C meningococcal conjugate vaccines (MenCC) risks induction of immunologic hyporesponsiveness. For this reason, MenCC vaccines are now used as probes of immunologic memory, however, no studies have demonstrated their ability to distinguish primed from unprimed children. Methods This study was part of a randomised controlled trial investigating the immunogenicity of a booster dose of the combined Haemophilus influenzae type b and MenC-tetanus toxoid vaccine (Hib-MenC-TT) in infants receiving reduced dose MenCC vaccine priming schedules (one MenC-CRM/MenC-TT or two MenC-CRM vaccine doses) compared with an unprimed group. Antibody kinetics were studied in a subset of 269 children by measuring changes in the MenC serum bactericidal antibody, using rabbit complement, (MenC rSBA) titres and MenC specific IgG memory B-cells before and at 6 and 28 days following the 12 month booster vaccination. Results At 6 days after the 12 month MenCC vaccine, the rise in MenC rSBA titres and MenC specific IgG memory B-cells of the primed groups were significantly higher than the infant MenCC naïve group. Participants primed with one MenC-TT dose had the highest increase in MenC rSBA titres compared with all other groups. The MenC rSBA titres at the 28th compared with the 6th day after boosting was significantly higher in those primed with a single MenC-TT/MenC-CRM vaccine in infancy compared with those who were not primed or who were primed with two doses of the MenC-CRM vaccine. Conclusion Immunologic memory can be demonstrated by a MenCC booster vaccination but is affected by the type and number of MenCC doses used for infant priming. The MenC rSBA responses can be used to demonstrate successful immunologic priming.

Original languageEnglish
Pages (from-to)6350-6357
Number of pages8
JournalVaccine
Volume34
Issue number50
DOIs
Publication statusPublished - 7 Dec 2016

Bibliographical note

Funding Information:
We would like to thank all children taking part in the study as well as their parents/guardians, the study staff in the research centres at Bristol, London, Malta, Oxford and Southampton and the NIHR Oxford Biomedical Research Centre, UK, the NIHR Medicines for Children Network South West and London (now NIHR Clinical Research Network: Paediatrics), the Southampton NIHR Wellcome Trust Clinical Research Facility and NIHR Respiratory Biomedical Research Unit, GlaxoSmithKline Biologicals, Belgium and European Society of Paediatric Infectious Diseases for financially supporting this study. The research team acknowledges the support of the National Institute for Health Research Clinical Research Network. AJP and MDS are Jenner Institute Investigators.

Publisher Copyright:
© 2016 Elsevier Ltd

Keywords

  • Capsular group C N. meningitidis
  • Immunologic memory
  • MenC glycoconjugate vaccines
  • MenC infant priming

Fingerprint

Dive into the research topics of 'Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy'. Together they form a unique fingerprint.

Cite this